NextCure (NASDAQ:NXTC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of NextCure (NASDAQ:NXTC) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other research firms have also commented on NXTC. HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Weiss Ratings upgraded shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, NextCure currently has a consensus rating of “Hold” and an average price target of $19.00.

NextCure Stock Performance

NASDAQ:NXTC opened at $7.71 on Friday. The stock has a fifty day moving average price of $3.89 and a 200-day moving average price of $8.18. The company has a market cap of $27.83 million, a price-to-earnings ratio of -0.89 and a beta of 1.26. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85). Research analysts predict that NextCure will post -8.11 EPS for the current fiscal year.

Insider Buying and Selling at NextCure

In other NextCure news, major shareholder Adar1 Capital Management, Llc acquired 36,303 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $4.94 per share, for a total transaction of $179,336.82. Following the transaction, the insider directly owned 722,419 shares in the company, valued at $3,568,749.86. This represents a 5.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders acquired 346,761 shares of company stock worth $1,710,807. 11.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in NextCure during the fourth quarter worth about $160,000. Millennium Management LLC acquired a new stake in shares of NextCure in the 4th quarter valued at approximately $185,000. Geode Capital Management LLC boosted its stake in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares in the last quarter. Cable Car Capital LP grew its holdings in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the last quarter. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.